-

SHAREHOLDER ALERT: Kaskela Law LLC Investigates Fairness of $9.60 Per Share Buyout Price for Pzena Investment Management, Inc. Shareholders (PZN) and Encourages Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Pzena Investment Management, Inc. (NYSE: PZN) (“Pzena”) on behalf of the company’s investors.

On July 26, 2022, Pzena announced that it would be acquired at a price of $9.60 per share in cash. Following the closing of the proposed transaction, Pzena’s shareholders will be cashed out of their investment position, and the company’s shares will no longer be publicly traded. As recently as February 2022, shares of Pzena’s stock traded above $10.50 per share.

The investigation seeks to determine whether Pzena shareholders will be receiving sufficient monetary consideration for their shares, and whether Pzena’s officers and directors violated the securities laws and/or breached their fiduciary duties in agreeing to sell the Company at $9.60 per share.

Pzena shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/pzena-investment-management/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation, and has helped recover in excess of $150 million on behalf of victimized investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

D. Seamus Kaskela, Esq.
skaskela@kaskelalaw.com
Adrienne Bell, Esq.
abell@kaskelalaw.com
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:PZN

Release Versions

Contacts

D. Seamus Kaskela, Esq.
skaskela@kaskelalaw.com
Adrienne Bell, Esq.
abell@kaskelalaw.com
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation into Fairness of $9.50 Per Share Global Business Travel Group (GBTG) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Kaskela Law is investigating the fairness of the recently announced buyout of Global Business Travel Group, Inc. (NYSE: GBTG) (“GBTG”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their GBTG shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/global-business-travel-group/ On May 4, 2026, GBTG announced that it had agreed to go privat...

Kaskela Law LLC Announces Shareholder Investigation of Playtika Holding Corp. and Encourages Investors with Losses to Contact the Firm – PLTK

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating Playtika Holding Corp. (NASDAQ: PLTK) (“Playtika”) on behalf of the company’s investors. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/playtika-holding/ Since July 2025, shares of Playtika’s common stock have declined in value from a trading price of over $4.50 per share to a current price of less than $3.50 per share, a decline of over 22%...

Kaskela Law LLC Announces Investigation into Fairness of $16.50 Per Share Select Medical Holdings (SEM) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating the fairness of the recently announced buyout of Select Medical Holdings Corp. (NYSE: SEM) (“Select Medical”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/select-medical/ On March 2, 2026, Select Medical announced th...
Back to Newsroom